SMO and skin basal cell carcinoma: Recently, posaconazole, a second-generation triazole antifungal with minimal drug–drug interaction and a favorable side-effect profile, has shown robust inhibitory activity against drug-resistant SMO mutants and against growth of HH-dependent BCC in vivo [104].